Company intelligence / Profile preview

Cullinan Pearl

Ownership: Private
Development stage: Other

Overview

Cullinan Pearl owned the global (excluding Japan) rights to zipalertinib (CLN-081/TAS6417), an orally available, irreversible EGFR inhibitor targeting exon 20 insertions. The drug received FDA Breakthrough Therapy Designation and was in ongoing pivotal studies for NSCLC harboring EGFR exon 20 mutations at the time of acquisition. Enrollment in key pivotal modules was on track for completion by the end of 2024.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Partnerships

Cullinan OncologyTaiho PharmaceuticalZai Lab

Beyond the preview

Go deeper on Cullinan Pearl.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cullinan Pearl.

Explore the full profile